Actinium Pharmaceuticals Inc. (ATNM) shares have gained 7.55% at $7.12 in Tuesday’s session as the leading radiotherapies developer is set to present its latest data in an upcoming major event. Actinium Pharmaceuticals (ATNM) stock finished last trading session at $6.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Which data ATNM will present?
Actinium Pharmaceuticals (ATNM) today featured its action at the impending Transplantation and Cellular Therapy (TCT) Tandem Meetings of ASTCT and CIBMTR.
- The meetings will be a combination of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), and will take place in Salt Lake City, Utah, from April 23 to 26, 2022.
- Boglarka Gyurkocza, M.D., examiner from Memorial Sloan Kettering Cancer Center, which was the most elevated choosing preliminary site in the SIERRA preliminary, will provide updated facts from the totally enlisted necessary Phase 3 SIERRA preliminary in an oral presentation.
- In addition, Actinium will lead clinical problems movement at TCT by collaborating with the bone marrow transplant (BMT) people group, which will include Iomab-B in a continuing medical education (CME) meeting.
- The conference will be led by Dr. Maritime Daver of The University of Texas MD Anderson Cancer Center and Dr. James Foran of the Mayo Clinical Cancer Center in Jacksonville, Florida, and will be titled “Tourist Spots Across the Patient Journey in AML, Applying Evidence with Novel Therapeutics Pre-and Post-AlloHCT.”
What does ATNM hold in store for you?
ATNM is excited to attend the TCT Tandem Meetings once more and present Iomab-B and the SIERRA preliminary at this premier bone marrow transplant and cell therapy event. Lomab-B has the potential to transform the way people think about targeted molding by allowing more people access to potentially corrective medications like BMT and focusing on long-term results with its own designated radiation system.
According to data from the SIERRA preliminary, all patients receiving Iomab-B had a consistent 100 percent rate of BMT access and engraftment, compared to only 17 percent of patients in the control arm who received various treatments, including recently approved designated treatments like Venetoclax, FLT-3, and IDH inhibitors.
How will ATNM present the information?
With topline data from SIERRA coming in the second quarter of this year, ATNM expects including SIERRA data in an oral presentation and highlighting it in the many TCT associations Actinium Pharmaceuticals (ATNM) has formed with BMT doctors, researchers, and guardians.